By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mallinckrodt Pharmaceuticals 

675 McDonnell Boulevard

Hazelwood  Missouri  63042  U.S.A.
Phone: 314-654-2000 Fax: 314-654-5381


Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.




Founder: Emil Mallinckrodt

CEO: Mark Trudeau

CFO: Matthew Harbaugh


Please click here for Mallinckrodt job opportunities.


All Products

Key Statistics

Ownership: Subsidiary

Web Site: Mallinckrodt
Symbol: MNK

Medical Device


Advanced Magnetics, Inc.  GastroMARK in North America

Company News
Validity Of Mallinckrodt (MNK)'s INOMAX Patent Claims Upheld 9/23/2016 7:17:56 AM
Mallinckrodt (MNK) Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products 9/1/2016 8:15:35 AM
Mallinckrodt (MNK) Receives FDA Fast-Track Designation For Synacthen Depot IND Application 8/25/2016 9:09:46 AM
Mallinckrodt (MNK) Selling Nuclear Imaging Biz to IBA Molecular in $690 Million Deal 8/24/2016 6:24:54 AM
Extracorporeal Photopheresis (ECP), Including Mallinckrodt (MNK)'s THERAKOS ECP Immunomodulation, Receives Approval For Reimbursement By Swiss Federal Department Of Home Affairs 8/23/2016 9:44:02 AM
Mallinckrodt (MNK) To Present At Wells Fargo Securities Healthcare Conference 8/19/2016 8:12:30 AM
Mallinckrodt (MNK) to Build New $80 Million+ Campus in New Jersey With Space for 400 Employees 8/18/2016 6:38:58 AM
Covidien (COV) Spinout Mallinckrodt (MNK) to Acquire Skin Substitute Developer Stratatech 8/11/2016 7:41:36 AM
Mallinckrodt (MNK) Reports Fiscal 2016 Third Quarter Results And Provides Guidance For Calendar Year 2016 8/2/2016 7:46:27 AM
First Patient Enrolled In Mallinckrodt (MNK) Phase 3 Terlipressin Trial 7/29/2016 6:14:25 AM